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Abstract: Cyclic STAT3 decoy (CS3D) is a second-generation, double-stranded oligodeoxynucleotide
(ODN) that mimics a genomic response element for signal transducer and activator of transcription
3 (STAT3), an oncogenic transcription factor. CS3D competitively inhibits STAT3 binding to target
gene promoters, resulting in decreased expression of proteins that promote cellular proliferation
and survival. Previous studies have demonstrated antitumor activity of CS3D in preclinical models
of solid tumors. However, prior to entering human clinical trials, the efficiency of generating the
CS3D molecule and its stability in biological fluids should be determined. CS3D is synthesized as a
single-stranded ODN and must have its free ends ligated to generate the final cyclic form. In this
study, we report a ligation efficiency of nearly 95 percent. The ligated CS3D demonstrated a half-life
of 7.9 h in human serum, indicating adequate stability for intravenous delivery. These results provide
requisite biochemical characterization of CS3D that will inform upcoming clinical trials.
Keywords: STAT3 as a drug target; cyclic STAT3 decoy; oligodeoxynucleotide inhibitor; head and
neck cancer
1. Introduction
Signal transducer and activator of transcription 3 (STAT3) is a highly regulated transcription
factor that plays a prominent role in cellular growth and survival, as well as inflammation [1,2]. STAT3
is activated by phosphorylation of tyrosine 705 by upstream kinases, including Janus kinases (JAKs).
Phosphorylation of STAT3 leads to homodimerization, translocation to the nucleus, and induction of
target gene expression. In normal cells, activation of STAT3 is typically transient. However, constitutive
hyperactivation of STAT3 has been observed in multiple human cancers, where it contributes to tumor
development [3,4]. Additionally, STAT3 signaling promotes resistance to conventional chemoradiation
and small-molecule inhibitors of other oncogenic signaling pathways [5–11]. Not surprisingly,
aberrant activation of STAT3 has been shown to correlate with poor clinical prognosis in a number of
malignancies [12–14]. Preclinical studies indicate that knockdown or inhibition of STAT3 selectively
causes apoptosis in cancerous cells and rescues sensitivity to the aforementioned therapies [3,4,15–17].
By contrast, abrogation of STAT3 signaling is substantially less deleterious to noncancerous cells, at least
in healthy adults [2,18]. In view of the pivotal role of STAT3 in human malignancies, a concerted effort
has been made over the past two decades to develop selective inhibitors of STAT3 signaling.
The blockade of upstream kinases (e.g., JAKs) is a well-validated strategy for inhibiting STAT3
activation and inducing anticancer effects [9,19–23]. Indeed, most currently advertised STAT3
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inhibitors target upstream activators. More recently, pharmaceuticals have been developed that
interfere with expression of the STAT3 protein [22,24]. Among these is AZD9150, a modified antisense
oligodeoxynucleotide (ODN) that targets STAT3 mRNA for destruction. AZD9150 has shown promise
in early clinical trials, reducing tumor burden in patients with refractory lymphoma and non-small cell
lung cancer [24]. It is currently being evaluated as monotherapy in patients with advanced solid tumors
and in combination with chemotherapy and/or durvalumab, an anti-PD-L1 monoclonal antibody
(NCT: 03421353).
STAT3 decoys utilize a distinct mechanism of action to inhibit signaling via the STAT3 pathway.
Based on a genomic response element bound by activated STAT3, the decoy molecules bind and inhibit
STAT3 dimers. A first-generation STAT3 decoy (S3D) was a linear double-stranded ODN, 15 base pairs
in length with free ends. This linear S3D inhibits the growth of solid tumors in preclinical models and
is well-tolerated in preclinical models [21,25–29]. In a Phase 0 clinical trial, intratumoral injection of
the linear S3D decreased expression of the STAT3 target genes encoding anti-apoptotic Bcl-XL and
pro-proliferative cyclin D1 [30]. In an effort to develop a STAT3 decoy formulation more resistant to
degradation by nucleases and, thereby, amenable to systemic delivery, hexaethylene glycol spacers
were covalently attached to the free ends of linear S3D to create the second-generation cyclic STAT3
decoy (CS3D) [30]. Although CS3D has demonstrated similar biological activity and safety as its linear
predecessor, the stability of CS3D in human serum has not been determined [26,30].
In the present study, we investigated the biochemical properties of CS3D. Since complete
cyclization of CS3D requires an enzymatic ligation step, we first determined the efficiency of this
ligation process. A biotinylated version of the CS3D was also generated, allowing pull-down of intact
CS3D from human serum samples and determination of stability. Our results demonstrate that CS3D
exhibits a roughly three-fold longer half-life in human serum compared to the first-generation linear
S3D, an improvement that will facilitate more effective systemic delivery in humans.
2. Results
2.1. Efficient Ligation of CS3D
CS3D is initially synthesized as a unimolecular, single-stranded sequence. Following
self-annealing at room temperature, enzymatic ligation with T4 DNA ligase is performed to generate
the completely cyclic molecule, CS3D (Figure 1A). To investigate the efficiency and consistency of
the ligation process, we performed multiple (n = 5) small-volume ligations using the same drug
stock and identical reaction conditions. Aliquots from each ligation reaction were then subjected to
electrophoresis on urea/polyacrylamide gels, followed by staining with SYBR Gold and quantification
of band intensity. On average, CS3D was ligated with 94.7 ± 0.5 percent efficiency (Figure 1B).
These results suggest that cyclization of CS3D through enzymatic ligation is a consistent and
reproducible process.
2.2. Biotinylation of CS3D Does Not Affect Ligation Efficiency
After establishing minimal variability between CS3D enzymatic ligations, we sought to compare
the stabilities of linear and cyclic STAT3 decoys in human serum. Previous studies have demonstrated
that covalent modifications to the terminal nucleotides of ODN decoys protect against serum
nucleases [31–34]. We hypothesized that flanking linear S3D with hexaethylene glycol spacers
and subsequent cyclization would shield the free ends from nucleolytic degradation in human
serum (Figure 2A). To enable quantitative determination of decoy levels in human serum, we
developed a pull-down assay to purify the decoys from the serum samples. The assay utilized
streptavidin-conjugated agarose resin to efficiently pull down biotinylated versions of S3D or CS3D.
In preliminary experiments, we first evaluated whether biotinylation would affect enzymatic ligation
of CS3D. As expected, biotinylation increased the molecular weight of CS3D, but had no observable
impact on ligation efficiency (Figure 2B).
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Figure 1. Efficient ligation of cyclic signal transducer and activator of transcription 3 (STAT3) decoy 
(CS3D). (A) Schematic representation of CS3D ligation with T4 DNA ligase. The complementary 
segments of the single-stranded decoy molecule spontaneously self-anneal. Enzymatic ligation with 
T4 DNA ligase was used to complete cyclization. (B) Incubations were performed in the absence or 
presence of T4 DNA ligase overnight. Multiple identical ligations (n = 5) were simultaneously 
performed. Samples from each reaction were then electrophoresed on a urea/polyacrylamide gel, 
stained with SYBR Gold, and quantified by densitometry. 
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Figure 2. Ligation of cyclic signal transducer and activator of transcription 3 (STAT3) decoy (CS3D) 
is unaffected by biotinylation. (A) Structures of parental and biotinylated STAT3 decoy (S3D) and 
CS3D. (B) CS3D and biotinylated CS3D were incubated with T4 DNA ligase overnight, followed by 
electrophoresis on a urea/polyacrylamide gel and staining with SYBR Gold. 
2.3. CS3D Demonstrates Greater Stability in Human Serum than Linear STAT3 Decoy (S3D) 
To determine the stabilities in human serum of the linear first-generation and cyclic second-
generation STAT3 decoys, the biotinylated decoys were incubated in fresh human serum for varying 
lengths of time, pulled down with streptavidin–agarose resin, and then analyzed on 
urea/polyacrylamide gels (Figure 3). Serum stability assays were performed in two different human 
serum samples for more reliable assessment of decoy half-lives (Figure 4A–D). The linear S3D 
exhibited an average half-life of 2.5 ± 1.2 h in the two serum samples (1.7 h in serum sample #1; 3.4 h 
in serum sample #2). CS3D, on the other hand, exhibited markedly enhanced resistance to 
degradation with an average half-life of 7.9 ± 2.0 h (6.5 h in serum sample #1; 9.3 h in serum sample 
#2). These findings underscore the improved stability of CS3D and its potential for clinical application 
as a systemically delivered agent.  
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2.3. CS3 e onstrates reater Stability in u an Seru than Linear STAT3 Decoy (S3D)
To deter ine the stabilities in human serum of the linear first-generation and cyclic
second-generation STAT3 decoys, the biotinylated decoys were incubated in fresh human serum
for varying lengths of time, pulled down with streptavidin–agarose resin, and then analyzed on
urea/polyacryla ide gels (Figure 3). Seru stability assays ere perfor ed in t o different hu an
seru samples for more reliable assessment of decoy half-lives (Figure 4A–D). The linear S3D exhibited
an average half-life of 2.5 ± 1.2 h in the two serum samples (1.7 h in serum sample #1; 3.4 h in serum
sample #2). CS3D, on the other hand, exhibited markedly enhanced resistance to degradation with an
average half-life of 7.9 ± 2.0 h (6.5 h in serum sample #1; 9.3 h in serum sample #2). These findings
underscore the improved stability of CS3D and its potential for clinical application as a systemically
delivered agent.
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Figure 3. Diagram of the serum stability assay. (1) Incubate biotinylated oligodeoxynucleotide (ODN) 
in fresh human serum. (2) Remove aliquots of ODN/serum mixture at various time points and store 
in −80 °C. (3) Incubate streptavidin resin with thawed aliquots of ODN/serum mixture. (4) Pellet and 
wash three times. (5) Elute by boiling, separate on urea/polyacrylamide gels, and develop with 
ultraviolet light. 
Figure 3. Diagram of the serum stability assay. (1) Incubate biotinylated oligodeoxynucleotide (ODN)
in fresh human serum. (2) Remove aliquots of ODN/serum mixture at various time points and store
in −80 ◦C. (3) Incubate streptavidin resin with thawed aliquots of ODN/serum mixture. (4) Pellet
and wash three times. (5) Elute by boiling, separate on urea/polyacrylamide gels, and develop with
ultraviolet light.
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Figure 4. Cyclic signal transducer and activator of transcription 3 (STAT3) decoy (CS3D) exhibits a 
longer half-life in human serum than linear STAT3 decoy (S3D). (A,C) Biotinylated S3D and CS3D 
were incubated in human serum samples #1 or #2 and aliquots were removed at varying time 
intervals, electrophoresed on urea/polyacrylamide gels, and stained with SYBR Gold. (B,D) 
Densitometric analyses were performed on biotinylated S3D and CS3D pulled down from serum. 
Stability at each time point was expressed as a percent relative to its respective “undigested” control. 
Undigested control represents decoy suspended in 1X phosphate-buffered saline (PBS) and lacking 
any serum. Each time point of the S3D and CS3D serum stability assays was performed in triplicate 
for each sample of human serum. 
3. Discussion 
Numerous solid tumor malignancies have been shown to exhibit oncogenic dependency on 
STAT3 [35,36]. However, no direct STAT3 inhibitors are currently used in clinical practice. Cyclic 
STAT3 decoy (CS3D), a double-stranded oligodeoxynucleotide (ODN) that competitively inhibits 
STAT3 binding to genomic response elements, has been shown to exert selective cytotoxicity against 
cancers with hyperactivated STAT3 [26,30,37]. To date, the stability of CS3D in human serum has 
remained unknown. In this study, we utilized a novel pull-down approach to measure the serum 
stabilities of CS3D, as well as an earlier linear version of the STAT3 decoy. By comparing the 
respective half-lives of the cyclic and linear STAT3 decoys, we determined that cyclization resulted 
in substantially improved stability in human serum. We further determined that the process of 
enzymatic ligation used to generate the cyclized CS3D is highly efficient and can likely be scaled up 
to generate large quantities of the inhibitor. Translating CS3D to the clinic will augment current 
treatment strategies for cancers that are characterized by dependence on STAT3 signaling. Moreover, 
successful application of CS3D will provide a foundation for the development and use of ODN 
decoys to target transcription factors in disease states including and beyond cancer. 
Transcription factor decoys comprise a class of nucleic acid-based agents that modulate the 
cellular activity of transcription factors, proteins that are often considered undruggable [38]. Decoys 
are short double-stranded ODNs designed to mimic the genomic sequences in target gene promoters 
that are recognized by transcription factors [39]. Although decoys have been studied in clinical trials 
for venous bypass graft vasculopathy and head and neck squamous cell carcinoma (HNSCC), 
instability represents a major translational hurdle because extracellular and intracellular nucleases 
rapidly degrade the free ends of linear ODN decoys [30,40–42]. In an effort to minimize such 
degradation, modifications at the free ends of decoy ODNs have been used to improve resistance 
against enzymatic activity. These modifications include the use of phosphorothioate linkers, 
unnatural nucleotides, and polyethylene glycol attachments [31–34]. Prior studies to assess the 
stabilities of modified ODNs have primarily focused on laboratory-generated aqueous solutions 
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ST T3 [35,36]. o ever, no direct ST T3 inhibitors are currently used in clinical practice. Cyclic
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stabilities of CS3D, as well as an earlier linear version of the STAT3 decoy. By comparing the respective
half-lives of the cyclic and linear STAT3 decoys, we determined that cyclization resulted in substantially
improved stability in human serum. We further determined that the process of enzymatic ligation
used to generate the cyclized CS3D is highly efficient and can likely be scaled up to generate large
quantities of the inhibitor. Translating CS3D to the clinic will augment current treatment strategies for
cancers that are characterized by dependence on STAT3 signaling. Moreover, successful application of
CS3D will provide a foundation for the development and use of ODN decoys to target transcription
factors in disease states including and beyond cancer.
Transcription factor decoys comprise a class of nucleic acid-based agents that modulate the cellular
activity of transcription factors, proteins that are often considered undruggable [38]. Decoys are short
double-stranded ODNs designed to mimic the genomic sequences in target gene promoters that are
recognized by transcription factors [39]. Although decoys have been studied in clinical trials for venous
bypass graft vasculopathy and head and neck squamous cell carcinoma (HNSCC), instability represents
a major translational hurdle because extracellular and intracellular nucleases rapidly degrade the free
ends of linear ODN decoys [30,40–42]. In an effort to minimize such degradation, modifications at
the free ends of decoy ODNs have been used to improve resistance against enzymatic activity. These
modifications include the use of phosphorothioate linkers, unnatural nucleotides, and polyethylene
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glycol attachments [31–34]. Prior studies to assess the stabilities of modified ODNs have primarily
focused on laboratory-generated aqueous solutions containing defined levels of human nucleases,
whereas the current study assessed decoy stability in human serum samples. Moreover, we developed
and utilized a novel pull-down assay, allowing us to easily purify intact, biotinylated decoys from the
serum. Our findings of improved stability with the cyclic STAT3 decoy confirm the value of modifying
or removing the free ends of decoy ODNs.
Although our results suggest that CS3D may be amenable to intravenous delivery in humans,
the optimal approach for targeted delivery to diseased tissue remains unclear. Strategies that have
been developed to enhance delivery include topical ointments, and the use of glycopolymers and
nanoparticles, among others [43–45]. Another method that has proven successful involves the use
of an ultrasound-targeted microbubble destruction (UTMD) system [46]. In this system, ODNs are
packaged into microbubbles that are delivered intravenously. An external ultrasound probe at the
desired delivery site facilitates rupture of the microbubbles, resulting in localized delivery. A previous
study using UTMD-mediated delivery of CS3D has demonstrated intratumoral uptake in a murine
model [47].
In summary, the use of cyclic ODN decoys may provide an effective strategy for targeting
transcription factors, including STAT3. However, no transcription factor decoys have yet been
translated to clinical practice. Our results reveal that fully cyclized CS3D can be efficiently generated via
enzymatic ligation. Moreover, CS3D demonstrates improved stability in human serum relative to linear
decoy with free ends. These findings will facilitate further clinical development of CS3D and provide
evidence supporting the potential use of transcription factor decoys as viable therapeutic agents.
4. Materials and Methods
4.1. Synthesis of Biotinylated Linear STAT3 Decoy (S3D) and Biotinylated Cyclic STAT3 Decoy (CS3D)
Biotinylated linear S3D was synthesized as two complementary single-stranded
oligodeoxynucleotides (ODNs) by Sigma-Aldrich (St. Louis, MO, USA). Biotinylated CS3D was
synthesized as a unimolecular single-stranded ODN by Integrated DNA Technologies (Skokie, IL, USA).
S3D and CS3D were reconstituted in normal saline as 800 µM stock solutions and stored at−20 ◦C.
4.2. Ligation of Cyclic STAT3 Decoy (CS3D) and Biotinylated CS3D
15 µL of single-stranded oligodeoxynucleotides (ODNs) were incubated with 3 µL of T4 DNA
ligase (400,000 U/mL; New England BioLabs, Ipswich, MA, USA, M0202S) and 2 µL of 10X T4
DNA ligase reaction buffer (New England BioLabs, B0202S) overnight at room temperature. Ligated
material was subsequently diluted to 1 µM, incubated with DNA loading buffer at 60 ◦C for 5 min,
and electrophoresed on 15% Tris-Borate-EDTA (TBE) urea/polyacrylamide gels. The ODNs were
detected by incubating gels in 1X SYBR Gold solution (Thermo Fisher Scientific, Waltham, MA, USA,
S11494) for 1 h at 4 ◦C in the dark, followed by exposure to ultraviolet light and image detection using
Azure c600 (Biosystems, Dublin, CA, USA). The relative densities of ligated and unligated ODN bands
were quantified using Image Studio Lite v5.2.5 (LI-COR Biosciences, Lincoln, NE, USA).
4.3. Annealing of Biotinylated Linear STAT3 Decoy (S3D)
Complementary sense and antisense strands of biotinylated linear S3D were incubated in
equimolar concentrations at 100 ◦C for 1 h, followed by annealing at room temperature overnight.
The annealed oligodeoxynucleotides (ODNs) were stored at 4 ◦C.
4.4. Serum Stability Assay
The stability of biotinylated ODNs in human serum was determined following incubation and
pull-down of the intact ODN [30,48]. Briefly, human serum was obtained from two individuals
in compliance with the Institutional Review Board of the University of California, San Francisco
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(IRB #14-15342). Biotinylated ODNs were incubated in 100% human serum at a final concentration of
0.05 µg/mL. After varying lengths of time, aliquots (20 µL) were removed and immediately stored at
−80 ◦C. After the final time point, each aliquot was incubated with streptavidin-coated agarose resin
(Pierce Streptavidin Resin, Thermo Fisher Scientific, 20347) for 60 min at room temperature, pelleted by
centrifugation, and washed 3 times in 3X phosphate-buffered saline (PBS) containing 0.05% Tween-20.
The pelleted resin was then resuspended in DNA loading buffer, followed by heating at 95 ◦C for
4 min to elute the ODNs. Supernatants were electrophoresed on 15% TBE urea/polyacrylamide gels
and visualized as described above. The optical densities of the samples were compared to the optical
densities of corresponding biotinylated ODNs suspended in 1X PBS that were not incubated in serum.
4.5. Statistical Analysis
Analyses of the serum stabilities of S3D and CS3D were performed using GraphPad Prism 5.04
(La Jolla, CA, USA).
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